Literature DB >> 23116409

A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 induction.

Yvonne Mårde Arrhén1, Hanna Nylén, Anita Lövgren-Sandblom, Kajsa P Kanebratt, Katarina Wide, Ulf Diczfalusy.   

Abstract

AIM: To compare plasma 4β-hydroxycholesterol : cholesterol with urinary 6β-hydroxycortisol : cortisol as markers of cytochrome P4503A4 activity before and after treatment with rifampicin for 2 weeks.
METHOD: 6β-hydroxycortisol and cortisol were determined by liquid chromatography tandem mass spectrometry and 4β-hydroxycholesterol was determined by gas chromatography-mass spectrometry in three groups of healthy volunteers.
RESULTS: Induction ratios for 6β-hydroxycortisol : cortisol were 1.8, 3.9 and 4.5 for 20 mg day(-1) , 100 mg day(-1) or 500 mg day(-1) of rifampicin, respectively. The corresponding ratios for 4β-hydroxycholesterol : cholesterol were 1.5, 2.4 and 3.8.
CONCLUSIONS: Plasma 4β-hydroxycholesterol : cholesterol gave similar induction ratios to urinary 6β-hydroxycortisol : cortisol.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23116409      PMCID: PMC3690112          DOI: 10.1111/bcp.12016

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Evaluation of 6β-hydroxycortisol, 6β-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo.

Authors:  C-C Peng; I Templeton; K E Thummel; C Davis; K L Kunze; N Isoherranen
Journal:  Clin Pharmacol Ther       Date:  2011-04-13       Impact factor: 6.875

2.  Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4.

Authors:  K Bodin; L Bretillon; Y Aden; L Bertilsson; U Broomé; C Einarsson; U Diczfalusy
Journal:  J Biol Chem       Date:  2001-08-20       Impact factor: 5.157

Review 3.  4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.

Authors:  Ulf Diczfalusy; Hanna Nylén; Pontus Elander; Leif Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

Review 4.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

5.  4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians.

Authors:  Ulf Diczfalusy; Jun Miura; Hyung-Keun Roh; Rajaa A Mirghani; Jane Sayi; Hanna Larsson; Karl G Bodin; Annika Allqvist; Mary Jande; Jong-Wook Kim; Eleni Aklillu; Lars L Gustafsson; Leif Bertilsson
Journal:  Pharmacogenet Genomics       Date:  2008-03       Impact factor: 2.089

6.  Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol.

Authors:  K P Kanebratt; U Diczfalusy; T Bäckström; E Sparve; E Bredberg; Y Böttiger; T B Andersson; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  2008-07-23       Impact factor: 6.875

7.  4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin.

Authors:  Ulf Diczfalusy; Kajsa P Kanebratt; Eva Bredberg; Tommy B Andersson; Ylva Böttiger; Leif Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2008-11-06       Impact factor: 4.335

  7 in total
  14 in total

1.  Distribution of Exogenous and Endogenous CYP3A Markers and Related Factors in Healthy Males and Females.

Authors:  Jieon Lee; Andrew HyoungJin Kim; SoJeong Yi; SeungHwan Lee; Seo Hyun Yoon; Kyung-Sang Yu; In-Jin Jang; Joo-Youn Cho
Journal:  AAPS J       Date:  2017-05-18       Impact factor: 4.009

2.  Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy.

Authors:  Shiri Shulman; Dafna Goldenberg; Roy Schwartz; Zohar Habot-Wilner; Adiel Barak; Nurit Ehrlich; Anat Loewenstein; Michaella Goldstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-03-21       Impact factor: 3.117

3.  Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.

Authors:  Sreeneeranj Kasichayanula; David W Boulton; Wen-Lin Luo; A David Rodrigues; Zheng Yang; Angela Goodenough; Michelle Lee; Mohammed Jemal; Frank LaCreta
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

4.  Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants.

Authors:  Jan de Jong; Donna Skee; Joe Murphy; Juthamas Sukbuntherng; Peter Hellemans; Johan Smit; Ronald de Vries; Juhui James Jiao; Jan Snoeys; Erik Mannaert
Journal:  Pharmacol Res Perspect       Date:  2015-06-24

5.  4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State.

Authors:  B M Wollmann; S W Syversen; E Lie; C Gjestad; L L Mehus; I C Olsen; E Molden
Journal:  Clin Transl Sci       Date:  2016-11-05       Impact factor: 4.689

Review 6.  The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo.

Authors:  Dmitrij A Sychev; Ghulam Md Ashraf; Andrey A Svistunov; Maksim L Maksimov; Vadim V Tarasov; Vladimir N Chubarev; Vitalij A Otdelenov; Natal'ja P Denisenko; George E Barreto; Gjumrakch Aliev
Journal:  Drug Des Devel Ther       Date:  2018-05-08       Impact factor: 4.162

Review 7.  Assessment of Vedolizumab Disease-Drug-Drug Interaction Potential in Patients With Inflammatory Bowel Diseases.

Authors:  Wan Sun; Richard A Lirio; Jennifer Schneider; Jiri Aubrecht; Harisha Kadali; Mike Baratta; Parul Gulati; Ajit Suri; Tiffany Lin; Raghavan Vasudevan; Maria Rosario
Journal:  Clin Pharmacol Drug Dev       Date:  2020-12-16

8.  Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.

Authors:  Catherine Dutreix; Sebastien Lorenzo; Yanfeng Wang
Journal:  Eur J Clin Pharmacol       Date:  2014-05-21       Impact factor: 2.953

9.  Mechanism Investigation of Rifampicin-Induced Liver Injury Using Comparative Toxicoproteomics in Mice.

Authors:  Ju-Hyun Kim; Woong Shik Nam; Sun Joo Kim; Oh Kwang Kwon; Eun Ji Seung; Jung Jae Jo; Riya Shresha; Tae Hee Lee; Tae Won Jeon; Sung Hwan Ki; Hye Suk Lee; Sangkyu Lee
Journal:  Int J Mol Sci       Date:  2017-07-02       Impact factor: 5.923

Review 10.  Personalized Drug Dosage - Closing the Loop.

Authors:  Geoffrey T Tucker
Journal:  Pharm Res       Date:  2016-12-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.